Merck: promising results for pneumococcal vaccine -November 28, 2023 at 09:16 am EST

Merck today announced the results of a Phase 3 trial evaluating V116, its investigational 21-valent pneumococcal conjugate vaccine specifically designed to protect adults. In adults aged 50 and over ,...

Related Keywords

Eliav Barr ,Merck Research Laboratories ,Head Of Global Clinical Development ,Senior Vice President ,Global Clinical Development ,Chief Medical Officer ,Merck Research ,Markets ,